Skip to content
PubMed This is a summary of 88 peer-reviewed journal articles Updated
Dermatology · Basal Cell Carcinoma

Skin Basal Cell Carcinoma (BCC): A Patient Guide

At a Glance

Basal cell carcinoma is usually slow-growing and localized, and most cases are cured with appropriate treatment. The choice between standard removal, Mohs surgery, or specialized creams depends on tumor features, followed by ongoing sun protection and professional skin checks.

Basal Cell Carcinoma (BCC) is the most common form of skin cancer, and while the word “cancer” can be deeply unsettling, BCC is distinct in its behavior and generally excellent outlook. Unlike more aggressive cancers that frequently travel to distant organs, BCC is almost always a localized condition that grows slowly and very rarely spreads throughout the body [1][2]. However, if neglected, it can be highly locally destructive and damage nearby tissue. Understanding this diagnosis begins with the reassurance that, with appropriate care, the vast majority of cases are successfully cured through straightforward medical procedures [3].

Note: This guide is meant to support, but not replace, individualized assessment and shared decision-making with your dermatologist or surgeon.

The nature of your treatment and the risk of the tumor returning are driven by a multifactorial assessment. Your care team looks at the tumor’s biological “subtype” (how it grows under a microscope), its physical location on your body, its clinical size, whether its borders are well-defined, your immune status, and whether the tumor has recurred after a previous treatment [4]. Subtypes describe the microscopic growth pattern of the cells—some stay in neat bundles, while others grow in thin strands that weave more deeply into the surrounding tissue [5]. When these more aggressive patterns appear in sensitive areas like the face, eyelids, or ears, or when they occur in patients with suppressed immune systems, the tumor is considered “high-risk.” This usually refers to the risk of local recurrence and the complexity of the treatment required [6].

Because of these variations, treatment is never “one size fits all.” For simple tumors on the trunk or limbs, standard surgical removal or even specialized creams may be highly effective. However, for tumors in high-risk zones or those with aggressive growth patterns, specialized techniques like Mohs micrographic surgery or other complete margin-assessment methods are often preferred to ensure every microscopic “root” is removed while sparing as much healthy tissue as possible [7][8]. Matching the right treatment to your specific risk level is the most important step in ensuring a successful outcome [9].

Once a BCC has been treated, the focus shifts toward long-term skin health and vigilance. Having one BCC is a clear signal that your skin is at a higher risk for developing new primary skin cancers in the future [10]. Living with this history means adopting a proactive approach to sun protection and committing to regular professional skin examinations. By staying observant and working closely with your dermatology team, you can manage this condition effectively and maintain healthy skin for the long term [11].

Common questions in this guide

What is the outlook for basal cell carcinoma?
Basal cell carcinoma usually grows slowly and almost always remains localized, so most cases have an excellent outlook when treated appropriately. If ignored, it can grow into and damage nearby tissue, which is why timely care matters.
Which features can make a BCC high risk?
Risk assessment considers the tumor’s microscopic subtype, size, border definition, location, immune status, and whether it has returned after treatment. Aggressive growth patterns in areas such as the face, eyelids, or ears, or in someone with a suppressed immune system, are considered high risk.
Why might Mohs surgery be recommended instead of standard removal?
Mohs micrographic surgery examines the edges of the removed tissue during the procedure to help find microscopic tumor roots. It is often preferred for BCCs in high-risk areas or with aggressive growth patterns because it can remove the tumor while preserving as much healthy tissue as possible.
What treatments are used for basal cell carcinoma?
Simple tumors on the trunk or limbs may be treated with standard surgical removal or specialized topical creams. Tumors in high-risk locations or with aggressive growth patterns may need Mohs surgery or another procedure that checks the entire tumor edge.
Does having one BCC increase my risk of another skin cancer?
Yes. Having one basal cell carcinoma is a signal that you have a higher risk of developing new primary skin cancers in the future. Regular professional skin examinations and consistent sun protection can help identify and address new changes early.
How should I protect and monitor my skin after BCC treatment?
Adopt a proactive daily sun-protection routine and remain alert to new or changing areas of skin. Continue regular professional skin examinations and ask your dermatology team how often you should be checked.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on skin basal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pathology report, how do the subtype, size, and clinical features of my BCC influence the treatment approach we are taking?
  2. 2.Why is the specific location of my tumor considered a 'high-risk' or 'low-risk' area?
  3. 3.What are the advantages of a complete margin-control surgery like Mohs for my specific case compared to standard removal?
  4. 4.How will we monitor my skin moving forward to catch any new developments early?
  5. 5.What changes should I make to my daily sun protection routine now that I have had a BCC diagnosis?

References

References (11)
  1. 1

    Diagnosis and management of basal cell carcinoma: interdisciplinary consensus statements of Jose R. Reyes Memorial Medical Center, a Department of Health Tertiary Hospital in Manila, Philippines.

    Ligeralde-Bascones KI, Gulmatico-Flores Z, Lim-Bueser HG, et al.

    International journal of dermatology 2023; (62(6)):812-821 doi:10.1111/ijd.16555.

    PMID: 36562635
  2. 2

    Global, regional and national burden of skin cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2035.

    Sun H, Fu J, Li J, et al.

    Medicine 2026; (105(27)):e49407 doi:10.1097/MD.0000000000049407.

    PMID: 42410801
  3. 3

    Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021.

    Hoashi T, Ishikawa M, Uehara J, et al.

    The Journal of dermatology 2024; (51(4)):e90-e105 doi:10.1111/1346-8138.16944.

    PMID: 38264942
  4. 4

    Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

    Bichakjian CK, Olencki T, Aasi SZ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(5)):574-97 doi:10.6004/jnccn.2016.0065.

    PMID: 27160235
  5. 5

    Histologically Agressive Basal Cell Carcinoma With Particular Emphasis On Galeal Infiltration Of The Scalp.

    Requena C, Serra-Guillén C, Sanmartín O

    Actas dermo-sifiliograficas 2022; (113(6)):575-582 doi:10.1016/j.ad.2022.01.026.

    PMID: 35339267
  6. 6

    Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma.

    Chen OM, Kim K, Steele C, et al.

    Cancers 2022; (14(15)) doi:10.3390/cancers14153720.

    PMID: 35954384
  7. 7

    Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods.

    Kauvar AN, Cronin T, Roenigk R, et al.

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2015; (41(5)):550-71 doi:10.1097/DSS.0000000000000296.

    PMID: 25868035
  8. 8

    Favourable results of Mohs micrographic surgery for basal cell carcinoma.

    Gniadecki R, Glud M, Mortensen K, et al.

    Danish medical journal 2015; (62(12)):A5171.

    PMID: 26621396
  9. 9

    Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).

    Xu YG, Lim Y, Bordeaux JS, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(9)).

    PMID: 39536442
  10. 10

    Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma.

    Wehner MR, Linos E, Parvataneni R, et al.

    JAMA dermatology 2015; (151(4)):382-8 doi:10.1001/jamadermatol.2014.3307.

    PMID: 25588079
  11. 11

    European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.

    Peris K, Fargnoli MC, Kaufmann R, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (192()):113254 doi:10.1016/j.ejca.2023.113254.

    PMID: 37604067

This BCC guide is for informational purposes only and does not constitute medical advice. Your dermatologist or surgeon should interpret your tumor’s subtype, location, and risk factors and recommend care for your situation.